Each cell in our body experiences up to tens of thousands of DNA-damaging events per day, primarily from routine cellular ...
Oncologists caution that at-home genetic tests taken up by millions of Americans looking to gauge their cancer risk are not ...
A Co Down woman, who received a shock diagnosis of ovarian cancer at just 55 years old, is pleading with Northern Ireland ...
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose . SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" ...
Dylan Horton was living his dream as a 23-year-old rookie defensive end for the Houston Texans when a call last October ...
On September 16, 2024, Immatics announced the proof-of-concept clinical data for the first candidate of its next-generation, ...
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...
"I feel like I have a responsibility to scream and shout loudly about it and say 'hey, this is killing women in Australia'," ...
AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback